Briacell Therapeutics Corp (BCTX)

$4.18 -0.34 (-7.52%)
Market Cap 31.25M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 191,100
Avg Vol 575,164
Day's Range N/A - N/A
Shares Out 7.25M
Stochastic %K 50%
Beta 1.46
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
Dadisong
Dadisong Mar. 21 at 7:12 PM
$BCTX es una empresa dirigida por un Judío, a está gente no le interesa el dinero ya es súper Rico, sólo le interesa y satisface joder al pobre y arruinarle más. No esperéis nada de ésta empresa nunca subirá y con el tiempo desaparecerá.
0 · Reply
GoldenChic
GoldenChic Mar. 20 at 2:59 PM
BINI $HUBC scam of the century $BCTX
0 · Reply
JediGreen
JediGreen Mar. 19 at 5:54 AM
$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 6:00 PM
$BCTX to showcase momentum at AACR - ALERTS, HOT STOCKS & CHARTS https://investorshangout.com/post/view?id=6820505
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 5:34 PM
$BCTX BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference https://www.globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html #BCTX #AACR2026 #BriaIMT #CancerImmunotherapy #BiotechStocks #BreastCancer #StockAlert @smallcapvoice
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 4:25 PM
Daily Hot Plays : $BCTX raises awareness on their positive... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177409709 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 3:53 PM
🚨 $BCTX AACR BREAKTHROUGH ALERT 🚨💯🚀 TODAY (March 18): BriaCell announces they will present POSITIVE Clinical Data from pivotal Phase 3 Bria-IMT™ + strong Preclinical Data for next-gen Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Annual Meeting! https://globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html ✅ Heavily pretreated metastatic breast cancer patients maintained quality of life + favorable safety profile (Phase 3 + Phase 2 data) ✅ Bria-OTS+ shows powerful activation of T-cells, NK cells & more across breast, prostate, lung & melanoma — broad cancer killer potential ✅ Four posters dropping April 17-22 in San Diego 🔥 DYOR | #BCTX #AACR2026 #BriaIMT #CancerImmunotherapy #BiotechStocks #BreastCancer #StockAlert @smallcapvoice
0 · Reply
tbagoni
tbagoni Mar. 18 at 3:47 PM
$BCTX Anyone know why down today? Although it is kind of low volume!
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 3:45 PM
Daily Hot Plays : $BCTX raises awareness on their positive... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177409709 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 3:39 PM
$BCTX raises awareness on their positive Phase 3 data for Bria-IMT™ and new preclinical results for Bria-OTS+™, highlighting efficacy, safety, and preserved quality of life in late-stage breast cancer. Read more about the posters here: https://globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html
0 · Reply
Latest News on BCTX
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Wed, 18 Mar 2026 07:30:00 -0400 - 3 days ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Tue, 10 Mar 2026 07:30:00 -0400 - 11 days ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 16 days ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:51:30.000Z - 4 weeks ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Wed, 18 Feb 2026 17:30:00 -0500 - 4 weeks ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 17 Feb 2026 07:30:00 -0500 - 4 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T13:30:56.000Z - 7 weeks ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Wed, 28 Jan 2026 07:30:00 -0500 - 7 weeks ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T13:32:37.000Z - 7 weeks ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Tue, 27 Jan 2026 07:30:00 -0500 - 7 weeks ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-19T16:00:45.000Z - 2 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

2026-01-16T13:58:57.000Z - 2 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Thu, 15 Jan 2026 16:05:00 -0500 - 2 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:36:30.000Z - 2 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T11:19:44.000Z - 2 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T10:55:53.000Z - 2 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

2026-01-14T06:56:44.000Z - 2 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 2 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T20:32:32.000Z - 2 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T14:08:02.000Z - 2 months ago

BriaCell Surge Above 50%; What's The Buzz?

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

2026-01-13T12:53:09.000Z - 2 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Tue, 13 Jan 2026 07:30:00 -0500 - 2 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Thu, 18 Dec 2025 07:30:00 -0500 - 3 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

2025-12-10T13:29:00.000Z - 3 months ago

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Wed, 10 Dec 2025 07:30:00 -0500 - 3 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

2025-12-09T13:34:16.000Z - 3 months ago

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Tue, 09 Dec 2025 07:30:00 -0500 - 3 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

2025-12-02T12:50:27.000Z - 3 months ago

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Tue, 02 Dec 2025 07:30:00 -0500 - 3 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

2025-12-01T12:53:14.000Z - 3 months ago

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Tue, 25 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

2025-11-20T13:28:07.000Z - 4 months ago

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Thu, 20 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Tue, 18 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Fri, 07 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Tue, 04 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

2025-10-28T08:01:00.000Z - 5 months ago

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

Top 3 Earnings Acceleration Buys for November

2025-10-27T19:05:00.000Z - 5 months ago

Top 3 Earnings Acceleration Buys for November

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

2025-10-22T12:51:17.000Z - 5 months ago

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Wed, 22 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

2025-10-21T20:52:14.000Z - 5 months ago

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

2025-10-21T13:25:38.000Z - 5 months ago

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

2025-10-21T12:50:54.000Z - 5 months ago

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Tue, 21 Oct 2025 07:50:00 -0400 - 5 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Tue, 21 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BriaCell (BCTX) Reports Promising Biomarker Data in Phase 3 Breast Cancer Study

2025-10-20T13:31:42.000Z - 5 months ago

BriaCell (BCTX) Reports Promising Biomarker Data in Phase 3 Breast Cancer Study

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Mon, 20 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell (BCTX) to Present Key Phase 3 Study Data at ESMO Congress 2025

2025-10-13T13:27:39.000Z - 5 months ago

BriaCell (BCTX) to Present Key Phase 3 Study Data at ESMO Congress 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 5 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 6 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 7 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 7 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 7 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 7 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 31, 2025, 7:30 AM EDT - 8 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 30, 2025, 7:30 AM EDT - 8 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 29, 2025, 7:30 AM EDT - 8 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 25, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 16, 2025, 4:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 15, 2025, 7:30 AM EDT - 8 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 9 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 10, 2025, 7:30 AM EDT - 9 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 9, 2025, 7:30 AM EDT - 9 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 8, 2025, 7:30 AM EDT - 9 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jul 2, 2025, 7:30 AM EDT - 9 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 24, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 4, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

Jun 2, 2025, 7:30 AM EDT - 10 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 27, 2025, 7:30 AM EDT - 10 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 23, 2025, 7:30 AM EDT - 10 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

BriaCell CEO Letter to Shareholders

May 20, 2025, 7:30 AM EDT - 10 months ago

BriaCell CEO Letter to Shareholders

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 30, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 4:05 PM EDT - 11 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 28, 2025, 7:30 AM EDT - 11 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 8:00 PM EDT - 11 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Dadisong
Dadisong Mar. 21 at 7:12 PM
$BCTX es una empresa dirigida por un Judío, a está gente no le interesa el dinero ya es súper Rico, sólo le interesa y satisface joder al pobre y arruinarle más. No esperéis nada de ésta empresa nunca subirá y con el tiempo desaparecerá.
0 · Reply
GoldenChic
GoldenChic Mar. 20 at 2:59 PM
BINI $HUBC scam of the century $BCTX
0 · Reply
JediGreen
JediGreen Mar. 19 at 5:54 AM
$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 6:00 PM
$BCTX to showcase momentum at AACR - ALERTS, HOT STOCKS & CHARTS https://investorshangout.com/post/view?id=6820505
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 5:34 PM
$BCTX BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference https://www.globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html #BCTX #AACR2026 #BriaIMT #CancerImmunotherapy #BiotechStocks #BreastCancer #StockAlert @smallcapvoice
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 4:25 PM
Daily Hot Plays : $BCTX raises awareness on their positive... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177409709 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 3:53 PM
🚨 $BCTX AACR BREAKTHROUGH ALERT 🚨💯🚀 TODAY (March 18): BriaCell announces they will present POSITIVE Clinical Data from pivotal Phase 3 Bria-IMT™ + strong Preclinical Data for next-gen Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Annual Meeting! https://globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html ✅ Heavily pretreated metastatic breast cancer patients maintained quality of life + favorable safety profile (Phase 3 + Phase 2 data) ✅ Bria-OTS+ shows powerful activation of T-cells, NK cells & more across breast, prostate, lung & melanoma — broad cancer killer potential ✅ Four posters dropping April 17-22 in San Diego 🔥 DYOR | #BCTX #AACR2026 #BriaIMT #CancerImmunotherapy #BiotechStocks #BreastCancer #StockAlert @smallcapvoice
0 · Reply
tbagoni
tbagoni Mar. 18 at 3:47 PM
$BCTX Anyone know why down today? Although it is kind of low volume!
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 3:45 PM
Daily Hot Plays : $BCTX raises awareness on their positive... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177409709 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 3:39 PM
$BCTX raises awareness on their positive Phase 3 data for Bria-IMT™ and new preclinical results for Bria-OTS+™, highlighting efficacy, safety, and preserved quality of life in late-stage breast cancer. Read more about the posters here: https://globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html
0 · Reply
SmallCapGrowth
SmallCapGrowth Mar. 18 at 3:34 PM
$BCTX to showcase momentum at AACR 2026 BriaCell will present positive Phase 3 data for Bria-IMT™ plus new preclinical results for Bria-OTS+™, highlighting efficacy, safety, and preserved quality of life in late-stage breast cancer. Read more about the posters here: https://globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html #BCTX #AACR2026 #BriaIMT #CancerImmunotherapy #BiotechStocks #BreastCancer #StockAlert
0 · Reply
Kirubin
Kirubin Mar. 18 at 1:56 PM
$BCTX you cannot write this shit up! Always finds a way to make BAG holders!😅
0 · Reply
kellymone2
kellymone2 Mar. 18 at 12:50 PM
$BCTX back to 6$ soon
1 · Reply
jfun1
jfun1 Mar. 18 at 11:54 AM
$BCTX Abstract Abstract is embargoed at this time.
0 · Reply
SmallCapVoice
SmallCapVoice Mar. 18 at 11:39 AM
$BCTX to showcase momentum at AACR 2026 BriaCell will present positive Phase 3 data for Bria-IMT™ plus new preclinical results for Bria-OTS+™, highlighting efficacy, safety, and preserved quality of life in late-stage breast cancer. Read more about the posters here: https://www.globenewswire.com/news-release/2026/03/18/3258061/0/en/BriaCell-to-Present-Positive-Clinical-Data-for-Bria-IMT-and-Preclinical-Data-for-Next-Generation-Bria-OTS-Personalized-Immunotherapy-at-the-2026-AACR-Conference.html
0 · Reply
2maligators
2maligators Mar. 18 at 1:38 AM
$BCTX can someone give us a rundown on the posters…
1 · Reply
hohumStocks
hohumStocks Mar. 17 at 9:15 PM
$BCTX https://www.abstractsonline.com/pp8/#!/21436/presentation/12137
1 · Reply
Moimic1995
Moimic1995 Mar. 17 at 8:58 PM
$BCTX i guess no one has the abstract
0 · Reply
jfun1
jfun1 Mar. 17 at 8:57 PM
$BCTX oh well. Guess not
0 · Reply
jfun1
jfun1 Mar. 17 at 7:46 PM
$BCTX do we run afterhours
0 · Reply
jfun1
jfun1 Mar. 17 at 7:46 PM
$BCTX Poster titles and presentation details will become available on March 17, 2026 at 4:30 PM ET, when the abstracts will be published in the online Proceedings of AACR.
0 · Reply
Manwiththeplan
Manwiththeplan Mar. 17 at 7:21 PM
$BCTX started a position here
0 · Reply